Connect with us

Trends

How wearable devices, IoT revolutionize healthcare monitoring

Among the many technologies that are now being integrated with healthcare systems are wearable devices. In effect, medical device manufacturers are now leveraging the Internet of Things (IoT) and the cloud to improve clinical workflow, help physicians remotely monitor patients with real-time data and analytics solutions and utilize innovative processes to cut costs and improve outcomes. For instance, novel wearable monitoring devices, equipped with the IoT technology, can communicate with smartphones, transferring crucial data into user friendly applications. Based on system components, the smartphones and smartwatches segment held the most significant share of the market, around 46.11%. And, according to data provided by Strategic Market Research, the digital biomarkers market is expected to grow at a CAGR of 35.7% to USD 23.31 Billion by 2030. Nemaura Medical Inc. (NASDAQ: NMRD), Planet Fitness, Inc. (NYSE: PLNT), Xponential Fitness (NYSE: XPOF), Novo Nordisk A/S (NYSE: NVO), Abbott Laboratories (NYSE: ABT)

Utilizing a remote patient monitoring system for ongoing well-being tracking can significantly contribute to averting the advancement of weight gain and mitigating potentially life-threatening medical issues, all while assisting the patient in their weight loss journey. Therefore, such devices can be helpful for patients combating obesity and those who struggle with weight loss. Obesity stands as a significant medical concern, elevating the likelihood of various other illnesses and health challenges, including but not limited to heart disease, diabetes, hypertension, elevated cholesterol levels, liver ailments, sleep apnea, and specific forms of cancer. Healthcare experts advise establishing a rigorous meal plan or dietary regimen that ensures an ample intake of essential components such as beneficial fats, carbohydrates, fiber, and proteins, as they are all pivotal for maintaining physical health. North America is expected to take the lead in the worldwide weight loss and weight management market, thanks to its increased availability of weight loss programs, whether through dedicated physical centers or online platforms.

Nemaura Medical Inc. announced breaking news earlier this week regarding, “interim results from its metabolic health program.

The primary objective of the study was to establish whether a metabolic program with a daily wear CGM worn twice a month resulted in greater engagement levels and sustainable weight reduction, and how this compared to other programs. The multi-centered study was run in collaboration with the UK’s National Health Service.

Known as Miboko (Mind, Body, Konnect), the program is the first to integrate a daily-wear and non-invasive glucose sensor with the Company’s bespoke app, educational content and AI driven analytics platform.

Users were invited to participate by their primary care practice, based on a BMI over 25. None of those invited to participate had expressed a willingness to join a metabolic weight loss program or had previously heard of the Miboko program. Participants used the Miboko app, and were given access to relevant education modules relating to aspects of metabolic health and weight loss. Diet and lifestyle were entered daily into the app, and weight was recorded weekly. Every two weeks, users wore the daily wear continuous glucose sensor, which tracked and displayed real-time glucose. At the end of the day, participants were provided with a Metascore® and measure of glucose variability.

In addition, users were presented with a video report which analysed their glucose trends and made diet and lifestyle recommendations. The Metascore® is derived from a number of factors including BMI, insulin sensitivity and lifestyle.

The study tracked 83 participants, with a mean age of 54 years old. The cohort was made up of 67% female (F), and 33% male (M), and 88% of participants recorded their ethnicity as ‘White’. After 20 weeks of enrolment, 59 people (16M/43F) had recorded weight loss, with 21 participants losing over 5KG (11 pounds). On an average basis, weight loss was 2.9KG (6.3 pounds) (1.9M/3.2F), with the rate of change increasing after week 8.

Qualitative feedback from users demonstrated substantially increased levels of understanding and empowerment on their weight loss goals, correlating to long-term behavioural changes that are pivotal to sustained weight loss. Of particular note is that users derived considerable benefit from their personalised insights, based on their Metascore® and response to diet and exercise. Verbatims from users confirmed that CGM sensor use increased user participation, better understanding of food choices and portion size.

After 20 weeks of use, the program had a retention rate of 32.5%. When active participants were asked whether they would continue with the program, 64% of respondents stated they were likely or very likely to continue to use the program. This far exceeds retention rates for health and wellbeing apps of 16.7% at 13 weeks and 6.9% at 26 weeks.1

Published studies report that affordability is a key barrier to CGM adoption, and the Company aims to price its CGM-embedded program significantly lower than any presently available comparable program.

The integration of Nemaura’s CGM sensor means that for the first time, a low-cost metabolic health improvement prevention program will soon be commercially available. The Company has the advantage of its own proprietary non-invasive sensor technology, which significantly reduces sensor costs, as the sensors are only worn a few days each month.
MB Bureau

Copyright © 2024 Medical Buyer maintained by Fullstack development

error: Content is protected !!